Qinlock (ripretinib)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- ripretinib
- Company
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Status
- Authorised
- Therapeutic area
- Gastrointestinal Stromal Tumors
- CHMP opinion
- Thu 16 Sep 2021
- EU approval
- Thu 18 Nov 2021
- Designations
- Orphan
- Application
- EMEA/H/C/005614
- ATC
- L01
- Official record
- www.ema.europa.eu
Indication
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Regulatory milestones
No milestones recorded in the last year.
Follow Qinlock
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.